Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer
NCT04634747
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
53
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Triple-Negative Breast Carcinoma
Interventions
DRUG:
PVX-410
Sponsor
OncoPep, Inc.